Saturday 17 October 2026
Export NUVB’s income statement to Excel — free account
Nuvation Bio Inc.
NUVB Healthcare Biotechnology
Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024. In the quarter to June 2026, revenue grew 555.6%, EPS fell 5.88%, free cash flow grew 10.6% and total debt rose 372.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.45
0.30
−6.32%
Follow NUVB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — | — |
Altman Z-Score |
3.64 | 0.66 | — | — | — | — | — | — |
P/S ratio |
48.65 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(2.01) | (0.84) | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — | — |
Beneish M-Score |
2.22 | — | — | — | — | — | — | — |
P/Operating CF |
(102.92) | (15.44) | — | — | — | — | — | — |
P/B ratio |
10.01 | 1.54 | — | — | — | — | — | — |
Price to Tangible BV |
10.39 | 1.56 | — | — | — | — | — | — |
EV/Sales |
41.08 | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
(14.90) | (1.70) | — | — | — | — | — | — |
EV/FCF |
(14.87) | (1.69) | — | — | — | — | — | — |
Quick Ratio |
6.67 | 8.91 | 44.00 | 50.41 | 45.40 | 33.10 | — | — |
Current Ratio |
6.95 | 9.04 | 44.11 | 50.70 | 45.62 | 33.69 | — | — |
Net Debt/EBITDA |
2.26 | 0.84 | 6.14 | 5.49 | 8.19 | 4.97 | — | — |
Debt/Assets |
8.90% | 1.16% | 0.00% | 0.63% | 0.39% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.17 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | — | — |
Asset Turnover |
0.11 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.85 | 0.23 | 0.90 | 0.92 | 0.79 | 0.88 | — | — |
Capex/Depreciation |
(3.48) | (0.24) | (0.25) | (1.79) | (1.53) | (1.41) | — | — |
Interest Coverage |
(15.57) | (1,737.91) | — | (16.08) | (31.49) | (22.39) | — | — |
| (53.18%) | (106.27%) | (12.03%) | (14.87%) | (18.07%) | (8.67%) | — | — | |
| (36.04%) | (97.74%) | (11.72%) | (14.39%) | (17.41%) | (37.57%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Return on Tangible Assets |
(41.77%) | (121.20%) | (12.57%) | (15.91%) | (11.49%) | (19.39%) | — | — |
Average Days of Receivables |
112.35 | 755.31 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
182.99% | 1,258.97% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
240.95% | 879.37% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Intangible Assets out of Total Assets |
0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
57.06% | 409.95% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.09 | 0.63 | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
(6.70%) | (84.96%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(5.68%) | (18.26%) | — | — | — | — | — | — |
Revenue per Share |
0.18 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Operating CF per Share |
(0.51) | (0.49) | (0.31) | (0.44) | (0.34) | (0.37) | — | — |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Free Cash Flow per Share |
(0.53) | (0.49) | (0.31) | (0.45) | (0.35) | (0.38) | — | — |
Cash per Share |
1.55 | 1.87 | 2.79 | 3.05 | 3.87 | 2.21 | — | — |
Shareholders Equity per Share |
0.90 | 1.73 | 2.76 | 3.02 | 3.77 | 2.21 | — | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
0.90 | 1.73 | 2.76 | 3.02 | 3.77 | 2.21 | — | — |
Free Cash Flow |
(181.78) | (130.57) | (68.05) | (96.46) | (68.47) | (36.67) | — | — |
Working Capital |
489.29 | 468.01 | 602.46 | 654.16 | 755.15 | 214.13 | — | — |
Capital Expenditures |
(8.35) | (0.16) | (0.05) | (0.36) | (0.28) | (0.14) | — | — |
Net Current Asset Value |
282.41 | 449.42 | 600.07 | 650.25 | 741.92 | 213.98 | — | — |
EV/EBIT |
0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
0.13 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
4.26 | 1.17 | 0.31 | 0.22 | 0.23 | 0.15 | — | — |
Cash ROIC |
(20.47%) | (13.42%) | (5.60%) | (7.31%) | (4.52%) | (8.51%) | — | — |
Accounts Receivable Turnover |
3.53 | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
1.18 | 1.65 | 0.00 | 0.16 | 0.12 | 0.03 | — | — |
Inventory Turnover |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
372.11 | 327.36 | 0.00 | 1,613.09 | 3,893.00 | 7,693.35 | — | — |
Days of Inventory on Hand |
447.95 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
17.83 | 10.00 | 3.09 | 2.76 | 2.07 | 2.07 | — | — |
Average Payables |
7.91 | 4.28 | 2.17 | 3.03 | 3.05 | 3.05 | — | — |
Average Assets |
567.72 | 581.06 | 646.81 | 724.15 | 498.97 | 110.90 | 0.00 | — |
Average Common Equity |
384.75 | 534.46 | 630.10 | 700.54 | 480.54 | 480.54 | — | — |
Columns are period end dates